Page last updated: 2024-11-07

sr 48692

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR 48692: structure in first source; a neurotensin receptor-1 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119192
CHEMBL ID506981
CHEBI ID125516
SCHEMBL ID1650932
MeSH IDM0211814

Synonyms (49)

Synonym
gtpl1582
meclinertant
reminertant
sr-48692
sr48692
PDSP2_000637
2-((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid
tricyclo(3.3.1.13,7)decane-2-carboxylic acid, 2-(((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl)carbonyl)amino)-
sr 48692
2-(((1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7) )decane-2-carboxylic acid
PDSP1_000642
CHEBI:125516
bdbm50248034
2-{[1-(7-chloro-quinolin-4-yl)-5-(2,6-dimethoxy-phenyl)-1h-pyrazole-3-carbonyl]-amino}-adamantane-2-carboxylic acid
L001448
CHEMBL506981 ,
2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
NCGC00242503-01
146362-70-1
MLS-0437456.0001
meclinertant [inn]
unii-5jbp4si96h
5jbp4si96h ,
BCP0726000168
BRD-K25075681-001-01-2
2-(((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl)carbonyl)amino)-tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid
MLS006010645
smr004701645
SCHEMBL1650932
2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl]carbonyl]amino]-tricyclo[3.3.1.13,7]decane-2-carboxylic acid
AKOS024457771
DTXSID40163360
J-507678
sr 48692, >=98% (hplc)
BCP03645
FT-0733910
113158-35-3
HY-105189
CS-0025250
DB06455
Q7392763
(1r,3r,5r,7r)-2-(1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1h-pyrazole-3-carboxamido)adamantane-2-carboxylic acid
2-[[1-(7-chloranylquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl]carbonylamino]adamantane-2-carboxylic acid
q6q ,
2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid.
S-265
tricyclo[3.3.1.13,7]decane-2-carboxylic acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1h-pyrazol-3-yl]carbonyl]amino]-
PD119349
E98718

Research Excerpts

Actions

ExcerptReferenceRelevance
"As SR 48692 could inhibit neurotensin induced cell growth, neurotensin receptor subtype-1 may serve as a therapeutic target for the therapy of pancreatic carcinomas."( Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1.
Cui, L; Li, HN; Li, NN; Wang, JG; Wang, P, 2011
)
1.1

Treatment

SR 48692 cotreatment had no effect on the development of sensitization to cocaine. Rats treated with SR 48692 made more reference and working memory errors during the acquisition of spatial learning.

ExcerptReferenceRelevance
"SR 48692 cotreatment had no effect on the development of sensitization to cocaine.(ABSTRACT TRUNCATED AT 250 WORDS)"( Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization.
Elsworth, JD; Horger, BA; Roth, RH; Taylor, JR, 1994
)
1.24
"Rats treated with SR 48692 made more reference and working memory errors during the acquisition of spatial learning than did rats infused with saline."( Microinfusions of neurotensin antagonist SR 48692 within the nucleus accumbens core impair spatial learning in rats.
Lázaro-Muñoz, G; Maldonado-Vlaar, CS; Rodríguez-González, V; Tirado-Santiago, G, 2006
)
0.92

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" There was a dose-response relationship between the magnitude of the hyperpolarization and the concentration of the peptide (10(-10)-10(-7)M); 10(-10)M being the threshold concentration."( Autoradiographic and electrophysiological evidence for the existence of neurotensin receptors on cultured astrocytes.
Hösli, E; Hösli, L; Stauffer, S, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency4.17630.001310.157742.8575AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neurotensin receptor type 2Homo sapiens (human)Ki0.41800.00050.04710.4180AID757775
Neurotensin receptor type 1Rattus norvegicus (Norway rat)IC50 (µMol)0.08200.08200.08200.0820AID1577245
Neurotensin receptor type 1Rattus norvegicus (Norway rat)Ki0.00260.00110.00180.0026AID757772
Neurotensin receptor type 1Homo sapiens (human)IC50 (µMol)0.04150.00020.00730.0820AID1182265; AID414520
Neurotensin receptor type 2Rattus norvegicus (Norway rat)Ki0.06200.00580.09170.6440AID1154142
SortilinHomo sapiens (human)IC50 (µMol)0.23800.23800.31110.3600AID757771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neurotensin receptor type 1Homo sapiens (human)EC50 (µMol)31.80002.710010.320019.6000AID602356; AID602427
Neurotensin receptor type 1Homo sapiens (human)EC50 (µMol)31.00000.00000.573610.0000AID1061686
Neurotensin receptor type 1Homo sapiens (human)Kd0.01840.00040.01300.0330AID388354; AID388355; AID388356; AID388357; AID388358; AID388359; AID388360
Neurotensin receptor type 2Rattus norvegicus (Norway rat)EC50 (µMol)0.12000.01800.07080.2170AID1154139
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neurotensin receptor type 1Rattus norvegicus (Norway rat)Ke0.00470.00150.01310.0230AID1154138
Neurotensin receptor type 1Homo sapiens (human)Ke0.03600.03500.03550.0360AID418188
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathwayNeurotensin receptor type 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayNeurotensin receptor type 2Homo sapiens (human)
sensory perceptionNeurotensin receptor type 2Homo sapiens (human)
regulation of membrane potentialNeurotensin receptor type 2Homo sapiens (human)
neuropeptide signaling pathwayNeurotensin receptor type 2Homo sapiens (human)
positive regulation of gene expressionNeurotensin receptor type 1Homo sapiens (human)
temperature homeostasisNeurotensin receptor type 1Homo sapiens (human)
negative regulation of systemic arterial blood pressureNeurotensin receptor type 1Homo sapiens (human)
regulation of membrane depolarizationNeurotensin receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayNeurotensin receptor type 1Homo sapiens (human)
neuropeptide signaling pathwayNeurotensin receptor type 1Homo sapiens (human)
chemical synaptic transmissionNeurotensin receptor type 1Homo sapiens (human)
learningNeurotensin receptor type 1Homo sapiens (human)
adult locomotory behaviorNeurotensin receptor type 1Homo sapiens (human)
positive regulation of glutamate secretionNeurotensin receptor type 1Homo sapiens (human)
positive regulation of gamma-aminobutyric acid secretionNeurotensin receptor type 1Homo sapiens (human)
response to lipidNeurotensin receptor type 1Homo sapiens (human)
positive regulation of apoptotic processNeurotensin receptor type 1Homo sapiens (human)
negative regulation of apoptotic processNeurotensin receptor type 1Homo sapiens (human)
regulation of respiratory gaseous exchangeNeurotensin receptor type 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painNeurotensin receptor type 1Homo sapiens (human)
negative regulation of release of sequestered calcium ion into cytosolNeurotensin receptor type 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolNeurotensin receptor type 1Homo sapiens (human)
positive regulation of inositol phosphate biosynthetic processNeurotensin receptor type 1Homo sapiens (human)
D-aspartate import across plasma membraneNeurotensin receptor type 1Homo sapiens (human)
inositol phosphate catabolic processNeurotensin receptor type 1Homo sapiens (human)
positive regulation of arachidonic acid secretionNeurotensin receptor type 1Homo sapiens (human)
positive regulation of inhibitory postsynaptic potentialNeurotensin receptor type 1Homo sapiens (human)
L-glutamate import across plasma membraneNeurotensin receptor type 1Homo sapiens (human)
ossificationSortilinHomo sapiens (human)
protein targeting to lysosomeSortilinHomo sapiens (human)
Golgi to endosome transportSortilinHomo sapiens (human)
endocytosisSortilinHomo sapiens (human)
G protein-coupled receptor signaling pathwaySortilinHomo sapiens (human)
neuropeptide signaling pathwaySortilinHomo sapiens (human)
endosome to lysosome transportSortilinHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSortilinHomo sapiens (human)
regulation of gene expressionSortilinHomo sapiens (human)
myotube differentiationSortilinHomo sapiens (human)
vesicle organizationSortilinHomo sapiens (human)
endosome transport via multivesicular body sorting pathwaySortilinHomo sapiens (human)
response to insulinSortilinHomo sapiens (human)
nerve growth factor signaling pathwaySortilinHomo sapiens (human)
negative regulation of fat cell differentiationSortilinHomo sapiens (human)
glucose importSortilinHomo sapiens (human)
neurotrophin TRK receptor signaling pathwaySortilinHomo sapiens (human)
plasma membrane to endosome transportSortilinHomo sapiens (human)
negative regulation of lipoprotein lipase activitySortilinHomo sapiens (human)
Golgi to lysosome transportSortilinHomo sapiens (human)
maintenance of synapse structureSortilinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityNeurotensin receptor type 2Homo sapiens (human)
G protein-coupled neurotensin receptor activityNeurotensin receptor type 2Homo sapiens (human)
G protein-coupled receptor activityNeurotensin receptor type 1Homo sapiens (human)
protein bindingNeurotensin receptor type 1Homo sapiens (human)
G protein-coupled neurotensin receptor activityNeurotensin receptor type 1Homo sapiens (human)
identical protein bindingNeurotensin receptor type 1Homo sapiens (human)
protein-containing complex bindingNeurotensin receptor type 1Homo sapiens (human)
protein bindingSortilinHomo sapiens (human)
nerve growth factor receptor activitySortilinHomo sapiens (human)
enzyme bindingSortilinHomo sapiens (human)
neurotensin receptor activity, non-G protein-coupledSortilinHomo sapiens (human)
nerve growth factor bindingSortilinHomo sapiens (human)
retromer complex bindingSortilinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
plasma membraneNeurotensin receptor type 2Homo sapiens (human)
plasma membraneNeurotensin receptor type 2Homo sapiens (human)
endoplasmic reticulumNeurotensin receptor type 1Homo sapiens (human)
Golgi apparatusNeurotensin receptor type 1Homo sapiens (human)
plasma membraneNeurotensin receptor type 1Homo sapiens (human)
cytoplasmic side of plasma membraneNeurotensin receptor type 1Homo sapiens (human)
cell surfaceNeurotensin receptor type 1Homo sapiens (human)
symmetric synapseNeurotensin receptor type 1Homo sapiens (human)
terminal boutonNeurotensin receptor type 1Homo sapiens (human)
dendritic spineNeurotensin receptor type 1Homo sapiens (human)
dendritic shaftNeurotensin receptor type 1Homo sapiens (human)
perikaryonNeurotensin receptor type 1Homo sapiens (human)
membrane raftNeurotensin receptor type 1Homo sapiens (human)
plasma membraneNeurotensin receptor type 1Homo sapiens (human)
lysosomeSortilinHomo sapiens (human)
lysosomal membraneSortilinHomo sapiens (human)
early endosomeSortilinHomo sapiens (human)
endoplasmic reticulum membraneSortilinHomo sapiens (human)
Golgi apparatusSortilinHomo sapiens (human)
cytosolSortilinHomo sapiens (human)
plasma membraneSortilinHomo sapiens (human)
clathrin-coated pitSortilinHomo sapiens (human)
cell surfaceSortilinHomo sapiens (human)
endosome membraneSortilinHomo sapiens (human)
membraneSortilinHomo sapiens (human)
clathrin-coated vesicleSortilinHomo sapiens (human)
trans-Golgi network transport vesicleSortilinHomo sapiens (human)
cytoplasmic vesicleSortilinHomo sapiens (human)
nuclear membraneSortilinHomo sapiens (human)
Golgi cisterna membraneSortilinHomo sapiens (human)
perinuclear region of cytoplasmSortilinHomo sapiens (human)
cerebellar climbing fiber to Purkinje cell synapseSortilinHomo sapiens (human)
membraneSortilinHomo sapiens (human)
Golgi apparatusSortilinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID388358Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 W134A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID414520Displacement of [125I]I-Tyr(3)NT from human NTR12009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy.
AID1182265Antagonist activity at NTSR1 (unknown origin) expressed in CHO cells assessed as inhibition of NT(8-13) peptide-induced change in intracellular Ca2+ level preincubated for 45 mins by FLIPR assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).
AID388356Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 H131A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID1577245Displacement of [125I]neurotensin from rat brain NTR12019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.
AID388359Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 F136A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID757772Displacement of [125I]NT from rat NTR1 transfected in mouse LTK cells2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757770Cytotoxicity against human LNCAP cells at >/= 50 uM after 5 days by CellTitre Glo assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757773Cytotoxicity against human C4-2B cells at >/= 50 uM after 5 days by CellTitre Glo assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID1154138Antagonist activity at rat NTS1 stably expressed in CHOK1 cells assessed as inhibition of NT-induced calcium release by FLIPR assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.
AID388355Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 F127A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID757771Binding affinity to NTR3 (unknown origin)2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757768Cytotoxicity against human SKOV3 cells at 100 uM by MTS assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID388360Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 W129A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID388357Displacement of [3H]SR48692 from human NTR1 extracellular loop 1 P133A mutant expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID700841Displacement of [125I]neurotensin from neurotensin receptor 1 in guinea pig brain2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
The many faces of the adamantyl group in drug design.
AID757774Cytotoxicity against human biculamide-resistant LNCAP cells at >/= 50 uM after 5 days by CellTitre Glo assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757775Binding affinity to NTR2 (unknown origin)2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757767Cytotoxicity against human SKOV3 cells at < 100 uM by MTS assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID757769Cytotoxicity against human C4-2B cells after 5 days by CellTitre Glo assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
AID418188Apparent affinity to NTR1 receptor expressed in CHOK1 cells2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.
AID1154140Agonist activity at rat NTS2 stably expressed in CHOK1 cells assessed as induction of calcium release by FLIPR assay relative to SR142948a2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.
AID388354Displacement of [3H]SR48692 from wild type human NTR1 expressed in HEK293 cells2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
AID1061686Agonist activity at NTR1 in human U2OS cells after 1 hr by beta-arrestin GFP reporter gene assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Imidazole-derived agonists for the neurotensin 1 receptor.
AID1061685Agonist activity at NTR1 in human U2OS cells after 1 hr by beta-arrestin GFP reporter gene assay relative to NT peptide2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Imidazole-derived agonists for the neurotensin 1 receptor.
AID1154142Displacement of [125I]NT at rat NTS2 overexpressed in CHOK1 cells after 30 mins by gamma counting2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.
AID1154139Agonist activity at rat NTS2 stably expressed in CHOK1 cells assessed as induction of calcium release by FLIPR assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346391Rat NTS1 receptor (Neurotensin receptors)1995Molecular pharmacology, May, Volume: 47, Issue:5
[3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
AID1346344Human NTS1 receptor (Neurotensin receptors)1997The Journal of pharmacology and experimental therapeutics, Feb, Volume: 280, Issue:2
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
AID1346344Human NTS1 receptor (Neurotensin receptors)2001Molecular pharmacology, Dec, Volume: 60, Issue:6
Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.
AID1346374Mouse NTS2 receptor (Neurotensin receptors)1998Biochemical and biophysical research communications, Feb-13, Volume: 243, Issue:2
Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism.
AID1346391Rat NTS1 receptor (Neurotensin receptors)1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Mutagenesis and modeling of the neurotensin receptor NTR1. Identification of residues that are critical for binding SR 48692, a nonpeptide neurotensin antagonist.
AID1346325Human NTS2 receptor (Neurotensin receptors)2001Molecular pharmacology, Dec, Volume: 60, Issue:6
Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (199)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's87 (43.72)18.2507
2000's72 (36.18)29.6817
2010's33 (16.58)24.3611
2020's7 (3.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.56 (24.57)
Research Supply Index5.33 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.48%)5.53%
Reviews5 (2.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other195 (96.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]